Synopsis

Source of validity: Scientific
Rating (out of 5): 2

2′-Fucosyllactose (2′-FL) is a human milk oligosaccharide (HMO) with well-documented prebiotic and immunomodulatory properties. Its potential role in supporting or treating Inflammatory Bowel Disorders (IBD), such as Crohn's disease and ulcerative colitis, is an area of active research. Preclinical studies in animal models have demonstrated that 2′-FL can modulate gut microbiota, enhance the growth of beneficial bacteria (notably bifidobacteria), and reduce intestinal inflammation. Some studies have shown that 2′-FL supplementation leads to increased production of short-chain fatty acids, improved intestinal barrier function, and dampened pro-inflammatory cytokine expression, all of which are relevant for IBD pathology.

However, direct evidence in humans with IBD is currently limited. Most research to date involves in vitro studies or animal models, with only a few small clinical trials focused on healthy adults or infants, not IBD patients specifically. Therefore, while the biological rationale and preclinical data are promising, clinical validation in IBD populations is lacking. At present, 2′-FL is not established as a standard therapy for IBD, but it is being investigated as a potentially adjunctive therapy to modulate gut health and inflammation.

In summary, the use of 2′-FL for IBD is supported by mechanistic and preclinical scientific evidence (earning a rating of 2), but robust clinical trials in humans with IBD are needed before it can be recommended as a treatment.

More about 2'-Fucosyllactose
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by 2'-Fucosyllactose

Products containing 2'-Fucosyllactose